Lefty2 Antibody

What is Lefty2 and why is it important in developmental biology?

Lefty2 (also known as Left-Right Determination Factor 2) is a member of the transforming growth factor beta (TGF-β) superfamily. It plays a crucial role in establishing left-right (L-R) asymmetry during mammalian development, particularly in organ systems like the heart and lungs. Additionally, Lefty2 may have significant functions in endometrial bleeding .

The protein functions as an antagonist of Nodal signaling, which is essential for proper embryonic development. Lefty2's importance is highlighted by the fact that mutations in the LEFTY2 gene have been associated with left-right axis malformations and certain types of infertility .

Unlike typical TGF-β family members, Lefty proteins have structural differences that affect their functioning:

• They lack the alpha-helical segment important for ligand dimerization

• They lack the cysteine residue involved in stabilizing dimers

• They act as monomers rather than dimers

What are the key differences between Lefty2 antibody types available for research?

Several types of Lefty2 antibodies are available for research, each with distinct characteristics:

When selecting an antibody, consider the specific application, target species, and whether epitope specificity (monoclonal) or broader detection (polyclonal) is more important for your research goals .

What is the expected molecular weight pattern for Lefty2 in Western blot applications?

Lefty2 typically appears at the following molecular weights in Western blot applications:

• Predicted full-length molecular weight: 41 kDa

• Observed molecular weights: 34-40 kDa

The discrepancy between predicted and observed weights can be attributed to several factors:

• Proteolytic processing: Lefty2 is synthesized as a 368 amino acid preproprecursor that undergoes proteolytic processing to generate the mature protein.

  • If cleavage occurs after Arg77, a 33-34 kDa mature form (aa 78-368) is produced, which is biologically inactive

  • If cleavage occurs after Arg135, a 27-28 kDa mature form (aa 136-368) is produced, which is biologically active

• Post-translational modifications: Glycosylation or other modifications can affect migration patterns

When interpreting Western blot results, it's important to know which form of Lefty2 your antibody recognizes. Some antibodies detect only mature forms, while others may recognize both precursor and mature forms .

What are the optimal protocols for using Lefty2 antibodies in immunohistochemistry?

For successful immunohistochemistry (IHC) with Lefty2 antibodies, follow these methodological guidelines:

Sample Preparation:

• Use formalin-fixed, paraffin-embedded (FFPE) tissue sections

• Recommended tissue types: human uterus/endometrium, endometrial cancer tissue, colon cancer tissue

Antigen Retrieval:

• Primary method: Heat-induced epitope retrieval with TE buffer pH 9.0

• Alternative method: Citrate buffer pH 6.0

Protocol:

• Deparaffinize and rehydrate tissue sections

• Perform antigen retrieval

• Block endogenous peroxidase activity and non-specific binding

• Incubate with primary antibody:

  • Rabbit polyclonal (ab229668): 1:100 dilution

  • Polyclonal (13991-1-AP): 1:20-1:200 dilution

  • Mouse monoclonal (ab115224): 10 μg/ml

• Apply appropriate biotinylated secondary antibody

• Visualize with chromogen (e.g., alkaline phosphatase streptavidin system)

• Counterstain, dehydrate, and mount

Controls:

• Positive control tissues: human endometrial cancer, colon cancer, uterus myometrium

• Negative control: omit primary antibody or use isotype control

Quality Assessment:

• Evaluate cellular localization, which should primarily be cytoplasmic

• Compare staining pattern with published literature

How can I optimize Western blot protocols for detecting Lefty2?

For optimal Western blot detection of Lefty2, consider these methodological recommendations:

Sample Preparation:

• Recommended cell/tissue lysates:

  • Human: A431 cells, HeLa cells

  • Mouse: uterus tissue, P19 embryonal carcinoma cells

• Use complete protease inhibitor cocktail during extraction

• Prepare samples under reducing conditions

Protocol Optimization:

• Protein loading: 20-50 μg total protein per lane

• Separation: 10-12% SDS-PAGE gel

• Transfer: PVDF membrane (recommended over nitrocellulose)

• Blocking: 5% non-fat milk or BSA in TBST

• Primary antibody incubation:

  • ab115224: 1:2000 dilution

  • ab229668: 1:1000 dilution

  • 13991-1-AP: 1:500-1:1000 dilution

  • AF7648: 2 μg/mL

• Secondary antibody selection:

  • Anti-rabbit IgG: 1:10000 dilution for rabbit primaries

  • Anti-sheep IgG: HRP-conjugated (HAF016) for sheep primaries

• Detection: ECL technique recommended

Troubleshooting:

• If multiple bands appear, confirm whether they represent different processed forms

• If weak signal, increase antibody concentration or extend incubation time

• Background issues may require more stringent washing or optimization of blocking conditions

Expected Results:

• Primary band at ~41 kDa (full-length)

• Potential additional bands at 33-34 kDa or 27-28 kDa (processed forms)

What are the best practices for immunofluorescence detection of Lefty2?

For optimal immunofluorescence (IF) detection of Lefty2, follow these methodological guidelines:

Sample Preparation:

• Cell types: HeLa cells, D3 mouse embryonic stem cells

• Fixation: 4% paraformaldehyde (most common)

• Permeabilization: 0.1-0.2% Triton X-100 in PBS

Protocol:

• Fix cells on coverslips

• Permeabilize cell membranes

• Block with 5% normal serum from the species of secondary antibody

• Incubate with primary antibody:

  • Polyclonal (13991-1-AP): 1:20-1:200 dilution

  • Sheep Anti-Mouse Lefty-2 (AF7648): 10 μg/mL for 3 hours at room temperature

• Wash thoroughly (3-5 times with PBS)

• Incubate with fluorophore-conjugated secondary antibody:

  • For AF7648: NorthernLights™ 557-conjugated Anti-Sheep IgG

• Counterstain nuclei with DAPI

• Mount with anti-fade mounting medium

Special Considerations:

• For enhanced detection of Lefty2, consider stimulating cells with Activin A, which has been shown to increase Lefty2 expression in D3 mouse embryonic stem cells

• Expected localization: primarily cytoplasmic

• Co-staining with markers of secretory pathway can provide insights into Lefty2 processing

Image Acquisition:

• Use appropriate filter sets for your fluorophores

• Capture Z-stacks if studying subcellular localization

• Include scale bars in all images

• Document exposure settings for comparative analyses

How can I distinguish between Lefty1 and Lefty2 in my experiments?

Distinguishing between Lefty1 and Lefty2 requires careful experimental design due to their significant homology. Mouse Lefty1 and Lefty2 share 95% amino acid sequence identity , making specific detection challenging but possible:

Antibody Selection:

• Choose antibodies raised against unique epitopes:

  • Look for antibodies specifically validated for non-cross-reactivity

  • Contact manufacturers for cross-reactivity data against both proteins

  • Consider using antibodies from Cell Signaling Technology (#12647) which has been specifically tested for Lefty1 specificity

RNA-Based Methods:

• Design RT-PCR primers targeting unique regions:

  • 3' UTR sequences are often divergent between paralogs

  • Design primers spanning unique exon junctions

  • Validate primer specificity with positive controls

• Use RNAscope or in situ hybridization with highly specific probes

Protein Detection Strategy:

• Perform sequential immunoprecipitation with antibodies against one paralog, then detect the other

• Use 2D gel electrophoresis to separate based on both molecular weight and isoelectric point

• Employ mass spectrometry to identify paralog-specific peptides

Functional Approaches:

• Create knockout/knockdown cell lines for each paralog individually

• Use CRISPR/Cas9 to tag endogenous proteins with different fluorescent markers

• Assess differential responses to Nodal pathway stimulation, as Lefty1 and Lefty2 may have subtle functional differences

Validation Controls:

• Always include samples with known expression of only Lefty1 or only Lefty2

• Consider using recombinant proteins as positive controls

• Verify results with multiple techniques when possible

What methodological approaches help characterize the interaction between Lefty2 and Nodal signaling?

Investigating Lefty2-Nodal interactions requires multiple complementary approaches:

Biochemical Interaction Assays:

• Co-immunoprecipitation (Co-IP):

  • Immunoprecipitate with anti-Lefty2 antibody

  • Probe for Nodal or Nodal receptors

  • Use recombinant tagged proteins if endogenous levels are low

• Surface Plasmon Resonance (SPR):

  • Measure binding kinetics between purified Lefty2 and Nodal

  • Determine association/dissociation constants

  • Compare with other TGF-β family antagonists

• Proximity Ligation Assay (PLA):

  • Visualize protein-protein interactions in situ

  • Use antibodies against Lefty2 and Nodal pathway components

  • Quantify interaction signals in different cellular compartments

Functional Signaling Assays:

• Luciferase Reporter Assays:

  • Use Nodal-responsive elements driving luciferase expression

  • Test inhibitory effects of wild-type vs. mutant Lefty2

  • Establish dose-response relationships

• Phospho-SMAD Analysis:

  • Western blot for phosphorylated SMAD2/3 after Nodal stimulation

  • Test Lefty2 inhibitory effects at different concentrations

  • Compare temporal dynamics of inhibition

• Target Gene Expression:

  • qRT-PCR for Nodal target genes (e.g., Pitx2)

  • Compare effects of Lefty2 knockdown/overexpression

  • Use RNA-seq for genome-wide effects on Nodal signaling

Structural Biology Approaches:

• X-ray crystallography or cryo-EM to determine Lefty2-receptor complex structures

• Molecular modeling to predict interaction interfaces

• Mutagenesis studies to validate key residues for interaction

In Vivo Models:

• Generate conditional knockout/knockin mouse models

• Analyze left-right asymmetry defects

• Use zebrafish models for rapid functional assessment

How should researchers interpret different processing forms of Lefty2 in their experiments?

Interpreting different processing forms of Lefty2 requires understanding the protein's maturation pathway and biological activity:

Understanding Lefty2 Processing:
Lefty2 is synthesized as a 368 amino acid preproprecursor that undergoes proteolytic processing:

• Signal sequence (aa 1-21): Removed during secretion

• Full proprecursor (aa 22-368): ~41-42 kDa

• Processed forms:

  • Cleavage after Arg77: 33-34 kDa mature form (aa 78-368) - biologically inactive

  • Cleavage after Arg135: 27-28 kDa mature form (aa 136-368) - biologically active

Methodological Approaches to Distinguish Forms:

• Western Blot Analysis:

  • Use antibodies targeting different regions of Lefty2

  • Antibodies against N-terminal regions may detect precursors but not mature forms

  • Compare reducing vs. non-reducing conditions

  • Use recombinant standards of known molecular weights

• Pulse-Chase Experiments:

  • Label newly synthesized proteins with radioactive amino acids

  • Chase with non-radioactive medium

  • Immunoprecipitate Lefty2 at different time points

  • Analyze processing kinetics

• Mass Spectrometry:

  • Identify specific cleavage sites

  • Characterize post-translational modifications

  • Quantify ratios of different forms

Functional Correlation:

• Compare biological activity with processing state

• Assess Nodal antagonism in relation to processing forms

• Create mutants at cleavage sites to prevent processing

• Correlate processing with developmental stage or pathological conditions

Interpretation Guidelines:

• Changes in the ratio of processed forms may indicate altered regulation

• Different cell types may exhibit different processing patterns

• Consider that processing may be spatiotemporally regulated during development

• Stress conditions may alter normal processing pathways

What are the methodological considerations when studying Lefty2 in stem cell pluripotency research?

Studying Lefty2 in stem cell pluripotency research requires specific methodological considerations:

Experimental Design:

• Cell Culture Systems:

  • Embryonic stem cells (ESCs): D3 mouse line shows Lefty2 expression

  • Induced pluripotent stem cells (iPSCs): Compare with ESCs

  • Embryoid bodies: Track Lefty2 during differentiation

  • Maintain defined culture conditions to ensure reproducibility

• Activation/Inhibition Approaches:

  • Activin A stimulation increases Lefty2 expression in D3 mouse ESCs

  • TGF-β pathway modulators affect Lefty2 levels

  • CRISPR/Cas9 for knockout/knockin studies

  • Doxycycline-inducible overexpression systems

Detection Methods:

• Protein Analysis:

  • Western blot optimization for stem cell lysates:

    • Recommended antibodies: AF7648 for mouse ESCs

    • Expected bands: 40-41 kDa

  • Immunofluorescence:

    • Lefty2 localizes to cytoplasm in stem cells

    • Co-stain with pluripotency markers (Oct4, Nanog)

  • Flow cytometry for quantitative analysis

• RNA Analysis:

  • qRT-PCR with validated primers

  • Single-cell RNA-seq to capture heterogeneity

  • RNA-FISH for spatial expression patterns

Functional Assays:

• Pluripotency Assessment:

  • Colony formation efficiency

  • Expression of core pluripotency factors

  • Differentiation capacity into three germ layers

  • Teratoma formation assays

• Signaling Pathway Integration:

  • Analyze effects on SMAD2/3 phosphorylation

  • Monitor interactions with other pluripotency pathways

  • Temporal dynamics during differentiation

  • Feedback regulation with Nodal signaling

Experimental Controls:

• Include wild-type and Lefty2-deficient cells

• Compare with Lefty1 effects

• Use small molecule inhibitors as complementary approaches

• Include species-appropriate positive controls

What are the most common issues when working with Lefty2 antibodies and how can they be resolved?

Researchers commonly encounter several issues when working with Lefty2 antibodies. Here are methodological solutions:

Problem: Weak or No Signal

Problem: Multiple Unexpected Bands in Western Blot

Problem: High Background in IHC/IF

Problem: Inconsistent Results Between Experiments

Quality Control Measures:

• Always include positive and negative controls

• Validate new antibody lots before extensive use

• Consider using recombinant Lefty2 as a standard

• Document all experimental conditions thoroughly

How can researchers validate the specificity of their Lefty2 antibody?

Validating antibody specificity is crucial for reliable Lefty2 research. Here's a comprehensive methodology:

1. Genetic Approaches:

• Knockout/Knockdown Controls:

  • Use CRISPR/Cas9 to generate Lefty2 knockout cells

  • Apply siRNA or shRNA to knockdown Lefty2

  • Compare antibody signal between control and knockout/knockdown samples

  • Signal should be absent or significantly reduced in knockout/knockdown samples

• Overexpression Systems:

  • Transfect cells with Lefty2 expression vectors

  • Include tagged versions (e.g., GFP-Lefty2) for dual detection

  • Compare antibody signal with tag detection

  • Signal should increase proportionally with overexpression

2. Biochemical Validation:

• Western Blot Analysis:

  • Run recombinant Lefty2 protein as positive control

  • Compare observed molecular weight (34-41 kDa) with predicted size

  • Perform peptide competition assay: pre-incubate antibody with immunizing peptide

  • Signal should be blocked by specific peptide but not by unrelated peptides

• Immunoprecipitation-Mass Spectrometry:

  • Immunoprecipitate with Lefty2 antibody

  • Analyze precipitated proteins by mass spectrometry

  • Confirm Lefty2 peptides in precipitated material

  • Assess for off-target binding proteins

3. Cross-Reactivity Assessment:

• Against Family Members:

  • Test reactivity with recombinant Lefty1, which shares high homology (95%)

  • Examine reactivity with other TGF-β family members

  • For human studies, check cross-reactivity between LEFTY-A and LEFTY-B

• Across Species:

  • Verify species reactivity claims by testing samples from multiple species

  • Mouse Lefty2 antibodies may not recognize human LEFTY2 due to sequence differences

4. Orthogonal Detection Methods:

• Correlation with mRNA Expression:

  • Compare protein detection with RT-PCR or RNA-seq data

  • Patterns should correlate across tissues/conditions

  • Discrepancies may indicate antibody issues or post-transcriptional regulation

• Multiple Antibody Comparison:

  • Use different antibodies targeting distinct epitopes of Lefty2

  • Compare staining patterns and signal intensities

  • Consistent results across antibodies increase confidence in specificity

What considerations should be made when selecting controls for Lefty2 antibody experiments?

Selecting appropriate controls is essential for reliable Lefty2 antibody experiments. Here's a methodological approach to control selection:

Positive Controls:

• Tissue/Cell Selection:

  • Human samples: endometrial cancer tissue, colon cancer tissue, A431 cells, HeLa cells

  • Mouse samples: uterus tissue, P19 embryonal carcinoma cells, D3 embryonic stem cells

  • Activin A-stimulated D3 mouse embryonic stem cells show enhanced Lefty2 expression

• Recombinant Protein Controls:

  • Purified recombinant 6X His-tagged human LEFTY2

  • Commercially available recombinant Lefty2 protein

  • Include at known concentrations for semi-quantitative analysis

• Overexpression Systems:

  • Transiently transfected cells with Lefty2 expression vectors

  • Stable cell lines with inducible Lefty2 expression

  • Tagged Lefty2 constructs for dual verification

Negative Controls:

• Technical Controls:

  • Primary antibody omission: reveals non-specific secondary antibody binding

  • Isotype controls: non-specific antibodies of same isotype and host species

  • Blocking peptide competition: pre-incubate antibody with immunizing peptide

• Biological Controls:

  • Lefty2 knockout/knockdown cells or tissues

  • Tissues known not to express Lefty2

  • Species without sequence homology (if such exists)

Specificity Controls:

• Related Protein Controls:

  • Samples expressing only Lefty1 to check cross-reactivity

  • Other TGF-β family members to assess family-wide cross-reactivity

  • For human studies: distinguish between LEFTY-A and LEFTY-B

• Application-Specific Controls:

  • For Western blot: molecular weight markers alongside samples

  • For IHC/IF: gradient of known expression levels

  • For IP: non-specific IgG from same species as primary antibody

Control Documentation:

• Record lot numbers of all antibodies and recombinant proteins

• Document exact protocol conditions for each control

• Include all controls in final data presentation

• Validate new batches of antibodies against established controls

How can Lefty2 antibodies be utilized in developmental biology research?

Lefty2 antibodies serve as valuable tools in developmental biology research through several methodological applications:

1. Spatiotemporal Expression Analysis:

• Embryonic Development Mapping:

  • Track Lefty2 expression during primitive streak formation

  • Map left-right asymmetric expression patterns

  • Correlate with developmental stages and key morphological events

  • Use whole-mount immunohistochemistry for 3D visualization

• Tissue-Specific Expression:

  • Examine expression in left lateral plate mesoderm

  • Map expression in developing heart, lungs, and other asymmetric organs

  • Compare with Nodal pathway component expression

  • Correlate with establishment of organ asymmetry

2. Regulatory Network Analysis:

• Signaling Pathway Interactions:

  • Co-immunostaining with Nodal pathway components

  • Quantify protein levels after pathway perturbations

  • Assess feedback regulation mechanisms

  • Map protein-protein interactions in developing tissues

• Transcriptional Regulation:

  • Combine with chromatin immunoprecipitation for transcription factor binding

  • Correlate protein expression with enhancer/promoter activity

  • Analyze effects of epigenetic regulators on Lefty2 expression

  • Integrate with transcriptomic data

3. Disease Model Applications:

• Congenital Asymmetry Disorders:

  • Analyze Lefty2 expression in heterotaxy models

  • Compare wild-type and mutant embryonic tissues

  • Correlate protein levels with severity of phenotypes

  • Examine potential therapeutic interventions

• Reproductive Biology:

  • Study endometrial expression in fertility models

  • Analyze expression changes during menstrual cycle

  • Investigate role in endometrial bleeding

  • Compare normal and pathological endometrial samples

4. Advanced Imaging Techniques:

• Super-Resolution Microscopy:

  • Visualize subcellular localization with nanometer precision

  • Track secretory pathway trafficking

  • Analyze co-localization with receptors or antagonists

  • Quantify molecular clustering at cell membranes

• Live Imaging Applications:

  • Generate knock-in fluorescent reporter models

  • Monitor protein dynamics in real-time

  • Track extracellular gradient formation

  • Correlate protein movement with morphological changes

What emerging techniques can enhance Lefty2 protein detection and functional analysis?

Several cutting-edge methodological approaches are emerging to advance Lefty2 research:

1. Advanced Antibody-Based Technologies:

• Proximity Ligation Assay (PLA):

  • Detect Lefty2 interactions with Nodal, receptors, or co-factors

  • Visualize interactions at single-molecule resolution

  • Quantify interaction dynamics in different cellular compartments

  • Combine with super-resolution microscopy for enhanced spatial resolution

• Mass Cytometry (CyTOF):

  • Multiplex Lefty2 with dozens of other proteins

  • Analyze at single-cell resolution

  • Create high-dimensional protein expression maps

  • Identify rare cell populations with unique Lefty2 expression patterns

2. Genetic Engineering Approaches:

• CRISPR/Cas9 Knock-in Strategies:

  • Generate endogenous fluorescent protein fusions

  • Create split-GFP systems for interaction studies

  • Introduce specific mutations to study processing

  • Develop degron-tagged versions for temporal control

• Optogenetic and Chemogenetic Tools:

  • Create light-activatable Lefty2 variants

  • Develop systems for spatiotemporal control of expression

  • Design synthetic receptors responsive to Lefty2

  • Engineer orthogonal signaling systems

3. Structural Biology and Biophysical Methods:

• Cryo-Electron Microscopy:

  • Determine high-resolution structures of Lefty2 complexes

  • Visualize conformational changes during receptor binding

  • Map epitopes for improved antibody design

  • Compare with other TGF-β family members

• Single-Molecule Methods:

  • Analyze Lefty2 diffusion using fluorescence correlation spectroscopy

  • Measure binding kinetics with single-molecule FRET

  • Study force-dependent interactions using optical tweezers

  • Track single-molecule dynamics in living cells

4. Systems Biology Integration:

• Multi-omic Integration:

  • Correlate Lefty2 protein levels with transcriptome and epigenome

  • Build predictive models of Lefty2 regulation

  • Map protein-protein interaction networks

  • Develop computational models of morphogen gradient formation

• Spatial Transcriptomics/Proteomics:

  • Map Lefty2 expression with spatial context

  • Correlate with spatial distribution of target genes

  • Analyze tissue microenvironments with single-cell resolution

  • Integrate with developmental atlases

How can researchers accurately quantify Lefty2 expression levels across different experimental systems?

Accurate quantification of Lefty2 requires tailored methodological approaches for different experimental systems:

1. Protein Quantification Methods:

• Western Blot Quantification:

  • Use recombinant Lefty2 standards at known concentrations

  • Create standard curves with 5-7 concentration points

  • Employ fluorescent secondary antibodies for wider linear range

  • Use housekeeping proteins (β-actin, GAPDH) for normalization

  • Account for different processed forms (34-41 kDa)

• ELISA Development:

  • Design sandwich ELISA with capture and detection antibodies

  • Validate with recombinant standards and knockout controls

  • Establish lower limit of detection and working range

  • Optimize sample preparation to prevent interference

2. Cell/Tissue Imaging Quantification:

• Immunohistochemistry Scoring:

  • Develop consistent scoring system (e.g., H-score, Allred)

  • Use digital image analysis for objective quantification

  • Account for heterogeneous expression patterns

  • Include calibration standards in each experiment

• Immunofluorescence Quantification:

  • Measure mean fluorescence intensity in regions of interest

  • Perform background subtraction and bleaching correction

  • Use Z-stack acquisition for 3D quantification

  • Consider automated segmentation for high-throughput analysis

3. Single-Cell Quantification:

• Flow Cytometry:

  • Optimize fixation and permeabilization for intracellular staining

  • Use fluorescence minus one (FMO) controls

  • Establish gates based on negative populations

  • Quantify both percentage positive and median fluorescence intensity

• Mass Cytometry (CyTOF):

  • Label antibodies with rare earth metals

  • Combine with other protein markers for cellular context

  • Perform high-dimensional analysis using clustering algorithms

  • Integrate with trajectory analysis for developmental studies

4. Secreted Protein Analysis:

• Conditioned Media Collection:

  • Standardize collection timeframes and cell densities

  • Consider concentration methods for low abundance detection

  • Account for matrix effects in complex media

  • Compare intracellular vs. secreted levels

• Multiplexed Assays:

  • Develop bead-based multiplexed assays

  • Measure Lefty2 alongside related TGF-β family members

  • Account for potential cross-reactivity

  • Normalize to total protein or cell number

5. Cross-Platform Normalization:

• Reference Standards:

  • Include identical reference samples across experiments

  • Use recombinant protein spikes at known concentrations

  • Develop conversion factors between different methods

  • Consider pooled internal controls for batch correction